<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-LDQHNR51</identifier><date>2019</date><creator>Rožman, Samo</creator><relation>documents/doc/L/URN_NBN_SI_doc-LDQHNR51_001.pdf</relation><relation>documents/doc/L/URN_NBN_SI_doc-LDQHNR51_001.txt</relation><format format_type="issue">2</format><format format_type="volume">70</format><format format_type="type">article</format><format format_type="extent">str. 139-144</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">3246715</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-LDQHNR51</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="eng">anaemia</subject><subject language_type_id="slv">anemija</subject><subject language_type_id="eng">cancer</subject><subject language_type_id="eng">erythropoiesis-stimulating agents</subject><subject language_type_id="eng">iron</subject><subject language_type_id="slv">rak</subject><subject language_type_id="slv">rekonbinantni eritropoetin</subject><subject language_type_id="slv">železo</subject><title>Management of anaemia and iron deficiency in patients with cancer</title><title>Obravnava anemij in pomanjkanja železa v onkologiji</title></Record>